Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LONDON--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced that the European Medicines Agency has authorized an update to the Summary of Product Characteristics (SmPC) for Baxter’s ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method, (in the EU, ADVATE, octocog alfa)] to include findings of the Phase IV prophylaxis study.
Help employers find you! Check out all the jobs and post your resume.
